Sponsor: 
Merck Sharp & Dohme (Australia)
Administration route: 
Subcutaneous injection
Vaccine group: 
Monovalent vaccines

Registered for use in people aged ≥12 months.

Monovalent varicella vaccine

Lyophilised powder in a monodose vial with a pre-filled diluent syringe.

Each 0.5 mL reconstituted dose contains:

  • ≥1350 plaque-forming units of live attenuated varicella-zoster virus (Oka/Merck strain)
  • 18 mg sucrose
  • 8.9 mg hydrolysed porcine gelatin
  • 3.6 mg urea
  • 0.36 mg monosodium glutamate monohydrate
  • residual components of MRC-5 cells

Also contains traces of:

  • neomycin
  • bovine serum

For Product Information and Consumer Medicine Information about Varivax visit the Therapeutic Goods Administration.

For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.

Page history

Last updated: 
27 September 2021
Last reviewed: 
27 September 2021